Tokyo-based Chugai Pharmaceutical (TYO: 4519) has won Japanese approval for additional dosing options for Hemlibra (emicizumab), a coagulation factor VIII substitute.
The therapy may be administered once weekly, every two weeks, or every four weeks, for routine prophylactic treatment for certain people with hemophilia A.
Chugai, which is majority-held by Swiss drugmaker Roche (ROG: SIX), is approved to market the therapy for people with hemophilia A with factor VIII inhibitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze